BioSpace News Archive

DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its second quarter 2020 financial results after market close on Tuesday, July 28, 2020. Management will hold a conference call to review the company’s second quarter 2020 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the DexCom, Inc. investor rela

Committed to continuous innovation and expansion of its service offerings, AGC Biologics has announced the expansion of its pDNA Center of Excellence in Heidelberg , Germany . The global biopharmaceutical Contract Development and Man

Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the second quarter ended June 30, 2020 on Wednesday, July 29, 2020 at 8:00 a.m. EDT.

AgBiome®, a leader in developing innovative products from the Earth’s microbial communities, announced a recent patent directed toward the Connate™ product line granted in the United States, further strengthening AgBiome’s IP Protection around novel product offerings

As the world struggles to find the best way to deal with Covid-19, experts agree on one thing: the importance of good testing.

Remote Patient Monitoring Solution Provides an Extra Layer of Safety and Offers Peace of Mind For Campus Reopenings

In patients with rheumatoid arthritis, higher disease activity — not post-operative flares — increases the risk of pain and poor function one year after a total hip arthroplasty or total knee arthroplasty, according to a new study by researchers at Hospital for Special Surgery in New York City.

SparingVision, a biotechnology company specializing in the research and development of innovative therapies for treatment of hereditary retinal degenerative diseases such as retinitis pigmentosa, announces today the decision of the European Commission to grant Orphan Drug Designation for SPVN06 for the treatment of inherited retinal dystrophies

Mezzion Pharma Co. Ltd. (140410.KQ), announced today that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the approval of udenafil to improve the physiology of patients 12 years of age and older with single ventricle heart disease (SVHD) who have undergone the Fontan operation

Gynesonics®, a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, announced the peer reviewed publication of CHOICES, a comparative, case-matched healthcare economic study.